SGS Poitiers Lab Receives GMP Certification
SGS Life Science Services announced that its bioanalytical laboratory in Poitiers, France has received GMP certification, following approval from ANSM.
SGS Life Science Services announced that its bioanalytical laboratory in Poitiers, France has received GMP certification, following approval from the Agence Nationale de Sécurité du Médicaments et des Produits de Santé (ANSM), the French agency charged with ensuring the quality of drug products. With this GMP certification, the laboratory can provide tests required for final batch release, the company reports in a press statement.
The GMP services will be performed in dedicated suites and controlled access areas of 200 square meters. The facility has been operating under GLP since 1994. With the Life Science Services laboratory in Clichy, France, the company provides services covering GMP activities for small and large molecules.
By bringing GMP to the Poitiers site, the company can offer cell-based assays for testing of biologics, including biosimilars. The company plans to bring bioanalytical capability to the West Coast of North America with a new facility in Carson, Cailf.
Source: SGS
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
